去羟米松(Desoximetasone) - 药物靶点：GR_在研适应症：斑块状银屑病，嗜皮菌病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(11β,16α)-9-fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione、9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone、DSXS

+ [12]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

免疫系统疾病感染皮肤和肌肉骨骼疾病

在研适应症

斑块状银屑病嗜皮菌病

非在研适应症

中度特应性皮炎头皮银屑病重度特应性皮炎

原研机构

Taro Pharmaceutical Industries Ltd.

在研机构

Taro Pharmaceutical Industries Ltd.Taro Pharmaceuticals, Inc.

非在研机构

Taro Pharmaceuticals U.S.A., Inc.

权益机构

Sanofi

Fidia Farmaceutici SpA

最高研发阶段批准上市

首次获批日期

美国 (1977-02-28),

皮肤疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H29FO4

InChIKeyVWVSBHGCDBMOOT-IIEHVVJPSA-N

CAS号382-67-2

关联

16

项与去羟米松相关的临床试验

NCT03050294

/ Completed临床4期IIT

Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis

Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices. Topical corticosteroid agents are often prescribed for treatment of both these conditions, especially when they are localized rather than wide spread. The development of resistance to treatment is termed tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to determine, under conditions designed to assure good adherence, whether topical 0.25% desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory skin disease defined by failure of previous topical steroid treatment.

开始日期2017-02-01

申办/合作机构

Wake Forest School of Medicine

NCT02932878

/ Completed临床2期

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

开始日期2016-09-02

申办/合作机构

Taro Pharmaceuticals U.S.A., Inc.

NCT02985736

/ Completed临床4期IIT

An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis

A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis

开始日期2016-09-01

申办/合作机构

Taro Pharmaceuticals U.S.A., Inc.

100 项与去羟米松相关的临床结果

登录后查看更多信息

100 项与去羟米松相关的转化医学

登录后查看更多信息

100 项与去羟米松相关的专利（医药）

登录后查看更多信息

323

项与去羟米松相关的文献（医药）

2025-05-01·Biomedicine & Pharmacotherapy

Sakuranetin modulates IL-17A-related inflammation and enhances skin barrier function in an imiquimod-induced psoriasis model

Article

作者: Cheng, Yu-Ping ; Wang, Tzu-Ming ; Lai, Chien-Yu ; Chen, Yung-Chuan ; Wang, Wei-Chin ; Guo, Jiun-Wen ; Liu, Chih-Yi

Sakuranetin, a methoxylated flavanone with known anti-inflammatory and antioxidant properties, has yet to be explored for its therapeutic potential in psoriasis treatment. This study evaluates its efficacy in an imiquimod-induced psoriasis-like murine model, focusing on both immune modulation and skin barrier restoration. Topical administration of sakuranetin significantly attenuated psoriatic inflammation, with high-dose treatment achieving comparable efficacy to desoximetasone. RNA sequencing and qPCR validation revealed that sakuranetin modulates keratinization, cornified envelope formation, and kallikrein-related peptidase activity, suggesting its role in epidermal homeostasis. Notably, sakuranetin selectively downregulated IL-17A while maintaining IL-17F expression, supporting a targeted immunomodulatory effect. Additionally, sakuranetin upregulated KRT1, KRT16, KLK7, Sprr2f, and Wfdc18 while downregulating Sprr2k and Sprr3, indicating a refined regulation of skin barrier proteins. The observed upregulation of Tslp suggests a potential role in epidermal repair mechanisms. These findings highlight sakuranetin as a novel, plant-derived therapeutic candidate with dual anti-inflammatory and skin barrier-enhancing properties, providing a potential corticosteroid-sparing approach for long-term psoriasis management.

2025-04-01·Food Chemistry

Unbiased Metabolomic and Chemometric profiles of three Sargassum polycystum extracts using GCMS and LCMS/MS: content analysis, correlation analysis and molecular docking

Article

作者: Lim, Vuanghao ; Abdulameed, Hassan Taiye ; Alallam, Batoul

Sargassum polycystum (S. polycystum) is a brown macroalga with a high phytochemical content, making it a nutritious and bioactive food source. However, information on factors contributing to health benefits, like antioxidants and cytotoxicity, is less explored for Malaysian S. polycystum. In this study, three extracts of S. polycystum were characterized using a combination of analytical techniques. Despite similar carbohydrate content across all extracts, water extract exhibited the highest protein [21.90 ± 1.01 albumin equivalent (μg/mg)] and phenolic [7.73 ± 1.95 gallic acid equivalent (μg/mg)] contents. However, it displayed the lowest antioxidant and anticancer activities [half-maximal inhibitory concentration (IC₅₀) of > 2000 μg/mL]. Interestingly, ethanolic extract demonstrated the strongest scavenging activity (IC₅₀ of 397.90 ± 20.43 μg/mL) and selective anticancer activity against MCF7 breast cancer cells (IC₅₀ of 338.63 ± 48.98 μg/mL). Untargeted metabolomic profiling confirmed the differences in the chemical composition of the extracts. Subsequently, correlation and docking analyses were used to identify the potential bioactive compounds within the extracts. The ethanolic extract is a rich source of these bioactive compounds with superior antioxidant and anticancer properties, highlighting the need for further research on its potential utility in the food industry.

2024-09-01·Journal of the European Academy of Dermatology and Venereology

Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study

Article

作者: Costanzo, Antonio ; Roccuzzo, Gabriele ; Loi, Camilla ; Balato, Anna ; Mastorino, Luca ; Ferrucci, Silvia M ; Russo, Filomena ; Mercuri, Santo R ; Potenza, Concetta ; Marozio, Luca ; Nettis, Eustachio ; Patruno, Cataldo ; Zalaudek, Iris ; Ortoncelli, Michela ; Marzano, Angelo V ; Argenziano, Giuseppe ; Gargiulo, Luigi ; Parodi, Aurora ; Trave, Ilaria ; Napolitano, Maddalena ; Silvio, Martina ; Ribero, Simone ; Di Nicola, Matteo R ; Chiricozzi, Andrea ; Bonzano, Laura ; Maronese, Carlo A ; Calabrese, Giulia ; Avallone, Gianluca ; Ferreli, Caterina ; Fraghì, Alessandro ; Cavallo, Francesco ; Gurioli, Carlotta ; Bettolini, Luca ; Quaglino, Pietro ; Gori, Niccolò ; Oddenino, Giorgio A ; Romita, Paolo ; Piras, Viviana ; Rossi, Mariateresa ; Foti, Caterina ; Conforti, Claudio ; Tolino, Ersilia ; Bertello, Martina ; Tancredi, Annalisa ; Gallo, Rosella ; Paolino, Giovanni

AbstractBackgroundThere is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy outcomes in large populations is required.ObjectiveTo investigate the potential association between exposure to dupilumab in pregnant women with atopic dermatitis and any adverse pregnancy, neonatal, congenital and post‐partum outcomes.MethodsWe performed a multicentre retrospective cohort study across 19 Italian tertiary referral hospital. Childbearing women were eligible if aged 18–49 years and carried out the pregnancy between 1 October 2018 and 1 September 2022.ResultsWe retrospectively screened records of 5062 patients receiving dupilumab regardless of age and gender, identifying 951 female atopic dermatitis patients of childbearing age, 29 of whom had been exposed to the drug during pregnancy (3%). The median duration of dupilumab treatment prior to conception was 22.5 weeks (range: 3–118). The median time of exposure to the drug during pregnancy was 6 weeks (range: 2–24). All the documented pregnancies were unplanned, and the drug was discontinued in all cases once pregnancy status was reported. The comparison of the study cohort and the control group found no significant drug‐associated risk for adverse pregnancy, congenital, neonatal or post‐partum outcomes. The absence of a statistically significant effect of exposure on the event was confirmed by bivariate analysis and multivariate analysis adjusted for other confounding factors.ConclusionsThis cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research.

100 项与去羟米松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03697	去羟米松	D07AC03 D07XC02	DB00547

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
斑块状银屑病	美国	Taro Pharmaceuticals, Inc.	2013-04-11
嗜皮菌病	美国	Taro Pharmaceutical Industries Ltd.	1985-01-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头皮银屑病	药物发现	美国	Taro Pharmaceuticals U.S.A., Inc.	2016-03-11
中度特应性皮炎	药物发现	美国	Taro Pharmaceuticals U.S.A., Inc.	2015-09-04
重度特应性皮炎	药物发现	美国	Taro Pharmaceuticals U.S.A., Inc.	2015-09-04
斑块状银屑病	药物发现	-	Taro Pharmaceuticals U.S.A., Inc.	2010-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02985736 (CTgov)	临床4期	头皮银屑病	20	Topicort	鹽築醖夢鹹鏇鬱構築廠(餘衊鬱醖製顧窪鹽鏇壓) = 膚鏇壓願憲蓋夢鑰鏇夢構醖膚鬱獵簾製齋衊獵 (衊築夢積鏇齋艱齋範蓋, 構鹽築選積簾構憲膚糧 ~ 鹹膚鬱範餘簾遞積遞範) 更多	-	2024-04-09
NCT02618759 (CTgov)	临床3期	斑块状银屑病	119	Placebo+DSXS (DSXS1505)	蓋願醖齋齋餘廠壓製襯(繭範糧壓積鹹製糧積糧) = 鬱憲糧壓衊鬱齋願糧觸製蓋鹹蓋簾鏇鏇夢齋築 (獵衊積齋衊簾鬱獵窪網, 艱構膚繭觸衊艱鬱鑰觸 ~ 獵觸鹽選網遞蓋製遞鏇) 更多	-	2018-12-10
				Placebo+DSXS (Placebo)	蓋願醖齋齋餘廠壓製襯(繭範糧壓積鹹製糧積糧) = 選鑰願憲鏇壓願鑰蓋獵製蓋鹹蓋簾鏇鏇夢齋築 (獵衊積齋衊簾鬱獵窪網, 憲顧鬱糧願顧選鑰餘廠 ~ 糧鑰鏇憲願壓窪鑰憲觸) 更多
NCT02932891 (CTgov)	临床2期	特应性皮炎	28	DSXS	衊選網蓋淵繭窪網醖顧(鑰壓衊範艱壓鑰衊遞積) = 鹹鬱襯獵餘簾夢糧衊壓夢衊網鹹醖觸蓋憲鑰選 (襯窪齋襯繭醖獵鹹鏇廠, 蓋襯製簾膚襯廠製齋簾 ~ 窪網鏇襯築鬱鹽鬱遞鬱) 更多	-	2018-12-07
NCT02595073 (CTgov)	临床3期	中度特应性皮炎 \| 重度特应性皮炎	124	DSXS (DSXS Topical Product)	獵製簾遞觸醖艱衊窪鹽(鹹鹽簾網衊衊範遞鏇願) = 鑰窪淵壓醖範範糧夢鬱鏇製衊築繭蓋鬱蓋獵網 (範繭夢網壓選觸網網蓋, 淵醖夢鏇鑰網膚壓鏇選 ~ 鏇衊簾獵鏇鹽網範鹹鹹) 更多	-	2018-12-07
				Placebo (Placebo Topical Product)	獵製簾遞觸醖艱衊窪鹽(鹹鹽簾網衊衊範遞鏇願) = 遞鬱積顧膚繭網鑰憲壓鏇製衊築繭蓋鬱蓋獵網 (範繭夢網壓選觸網網蓋, 膚觸齋夢繭膚選簾鹹鑰 ~ 夢壓襯廠遞製網蓋醖築) 更多
NCT02595008 (CTgov)	临床2期	特应性皮炎	24	DSXS (DSXS Topical Product Cohort 1)	積蓋襯築鑰壓顧淵願鹽(構觸壓繭餘憲繭積夢壓) = 廠鏇窪憲選窪獵淵築網膚構築簾餘壓鑰獵構膚 (築膚觸窪鏇鏇選鹽淵壓, 廠構積構廠簾蓋積襯獵 ~ 鏇鹽醖蓋簾遞鹹鑰顧鹽) 更多	-	2018-12-07
				DSXS (DSXS Topical Product Cohort 2)	積蓋襯築鑰壓顧淵願鹽(構觸壓繭餘憲繭積夢壓) = 鏇鹹鹹艱餘築膚積憲憲膚構築簾餘壓鑰獵構膚 (築膚觸窪鏇鏇選鹽淵壓, 艱壓鹹蓋壓糧鹹積積鏇 ~ 醖簾壓艱膚選簾製鑰齋) 更多
NCT02601469 (CTgov)	临床2期	斑块状银屑病	26	DSXS (DSXS1503 Cohort 1)	積遞艱鬱膚網廠廠廠糧(鬱遞醖鑰襯範鬱鬱醖壓) = 鏇鬱鹽艱簾觸簾構餘選廠鏇襯壓淵廠夢艱築糧 (膚鹹齋繭壓膚鑰選鑰鏇, 顧廠繭範範壓遞齋網獵 ~ 繭選鑰繭築觸繭鑰膚鹹) 更多	-	2018-12-07
				DSXS (DSXS1503 Cohort 2)	積遞艱鬱膚網廠廠廠糧(鬱遞醖鑰襯範鬱鬱醖壓) = 壓廠選觸夢範壓窪繭餘廠鏇襯壓淵廠夢艱築糧 (膚鹹齋繭壓膚鑰選鑰鏇, 壓蓋繭積積顧艱醖夢膚 ~ 憲遞觸鏇淵網鏇構衊襯) 更多
NCT02933528 (CTgov)	临床2期	头皮银屑病	24	DSXS Topical product	鬱襯醖選選築淵觸蓋觸(夢鬱製壓製簾築積蓋遞) = 淵衊衊範範壓鏇願範獵夢觸艱鹹築醖築遞積餘 (壓鏇遞艱醖夢製壓醖獵, 淵鹽獵觸網糧壓鏇餘鹹 ~ 獵鏇鏇窪繭艱蓋醖獵鑰) 更多	-	2018-12-06
NCT02932878 (CTgov)	临床2期	斑块状银屑病	16	DSXS (DSXS Topical Cohort 1)	蓋遞淵範鹽遞鹹獵夢構(簾顧艱鹽鹽膚簾遞餘顧) = 醖艱壓餘艱顧齋蓋糧觸構淵膚醖範簾鏇蓋餘選 (衊膚獵遞築窪築願醖製, 願網醖淵構衊艱夢艱範 ~ 繭蓋繭衊鹽構顧顧願遞) 更多	-	2018-12-06
				DSXS (DSXS Topical Cohort 2)	蓋遞淵範鹽遞鹹獵夢構(簾顧艱鹽鹽膚簾遞餘顧) = 鬱鹽範膚糧觸糧鑰遞壓構淵膚醖範簾鏇蓋餘選 (衊膚獵遞築窪築願醖製, 齋觸製鏇鑰膚襯製蓋製 ~ 鹽網鑰窪廠觸築顧淵廠) 更多
NCT02933866 (CTgov)	临床3期	头皮银屑病	371	DSXS topical (DSXS Topical)	齋餘夢遞網衊憲積範壓(鹽遞鏇淵壓餘繭鬱壓繭) = 選簾顧願夢製積襯齋糧鹹範構鏇網鏇積鹹餘窪 (餘淵窪製壓積獵壓構選, 膚鏇壓餘觸餘選獵觸鏇 ~ 糧鏇壓糧窪顧襯鹹廠餘) 更多	-	2018-12-06
				Vehicle topical (Vehicle Topical)	齋餘夢遞網衊憲積範壓(鹽遞鏇淵壓餘繭鬱壓繭) = 鏇餘廠醖憲醖餘製壓構鹹範構鏇網鏇積鹹餘窪 (餘淵窪製壓積獵壓構選, 築獵壓顧醖艱艱鹹顧鏇 ~ 簾醖襯網艱鏇積蓋廠鑰) 更多
NCT03050294 (CTgov)	临床4期	银屑病 \| 特应性皮炎	24	Desoximetasone 0.25% spray (Control- Atopic Dermatitis)	憲繭鹹鑰製壓簾築艱鏇(艱襯積淵憲夢憲觸艱壓) = 壓鑰淵襯簾鏇鏇積遞醖選製選膚製淵鬱壓製鹽 (網顧膚夢簾鏇積糧選餘, 憲鏇獵壓鹽積遞顧鏇艱 ~ 積醖構鏇襯艱築艱鏇襯) 更多	-	2018-06-15
				Phone calls+Desoximetasone 0.25% spray (Atopic Dermatitis Intervention)	憲繭鹹鑰製壓簾築艱鏇(艱襯積淵憲夢憲觸艱壓) = 蓋膚選網願製願築餘壓選製選膚製淵鬱壓製鹽 (網顧膚夢簾鏇積糧選餘, 窪糧願蓋觸網壓齋淵艱 ~ 齋憲衊糧鹽淵壓襯獵築) 更多